The fourth edition of this report provides an overview of the life sciences research tools market from 2013 to 2021. Life sciences research tools companies offer instruments, reagents and services to academic, BioPharma, applied market and (non-IVD) clinical customers. This market is consolidated, with top vendors including Agilent, Bio-Rad, Illumina, Life Technologies*, MilliporeSigma, and Thermo Fisher representing the majority of sales; however, mid-size players (e.g., Luminex, NanoString) and smaller emerging players are highlighted and included in this report as well (e.g., Oxford Nanopore, Quanterix, Seahorse Biosciences***).
As in previous versions, we carefully triangulated market growth with past and forecasted organic growth from keys players, many of which have experienced growth driven by acquisition. As a result, segmenting the market by technology, we estimate that the life science research tools market will reach $52.5B in 2017, and is expected to grow ~5% p.a. in the next 4 years. These figures are in contrast with other reports on individual technologies that report bullish growth rates of 5%-20% for many technologies. Our analysis confirms that within academia, growth will continue to be strong in emerging markets (e.g., China, India) offset by weakness in academic funding in developed countries (e.g., Japan, Europe). With that said, our analysis confirms that applied markets (such as non-IVD clinical / LDT’s, forensics or AgBio customers) might experience double digit growth for many technologies. This report evaluates which technologies are expected to capture (e.g., NGS, mass spectrometry) and lose (e.g., PCR) relative market share.
For each of these 35 subsegments, we present an analysis detailing sales of instruments and reagents for 2013, 2017 and 2021. In addition, we detail market drivers (e.g., increased government funding in emerging markets) and moderators (e.g., pricing pressure for some technologies), market trends (e.g., shift of pharma interest from small molecule to large molecule drugs, interest in single cell analysis), a high level end-customer breakdown (Academic, BioPharma and Applied markets customers) and key competitors.
All data are based on manufacturer sales as publicly reported, and a total of 37 interviews^^ with life sciences experts in academic, BioPharma and applied market laboratories conducted.
Dr. Budel specializes in the market analysis of private to mid-cap companies with emerging to established technologies in the life science research tools and diagnostic spaces. He has deep genomics expertise, especially as it relates to clinical NGS. He has supported clients facing a broad range of challenging business issues, including R&D prioritization, evaluation of disruptive technologies, and commercial due diligences.
Schedule a 15-minute report demo with Stephane today!